Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: A retrospective case series

Journal of Neuro-Oncology

Volumn 114, Issue 2, 2013, Pages 237-240

  Chamberlain, Marc C ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Alkylator refractory; BRAF inhibitor; Recurrent pleomorphic xanthoastrocytoma (PXA); Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VEMURAFENIB; VINCRISTINE; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTHRALGIA; ARTICLE; BRAF GENE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; GAMMA KNIFE RADIOSURGERY; GENE; GENE MUTATION; HUMAN; KERATOACANTHOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROSURGERY; OFF LABEL DRUG USE; OVERALL SURVIVAL; PHOTOSENSITIVITY; PLEOMORPHIC XANTHOASTROCYTOMA; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ASTROCYTOMA; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROCEDURES;

ADULT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SULFONAMIDES;

EID: 84885059781     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1176-5     Document Type: Article

References (17)

1. Perkins SM, Mitra N, Fei W, Shinohara ET (2012) Patterns of care and outcome of patients with pleomorphic xanthoastrocytoma: a SEER analysis. J Neurooncol 110(1):99-104. doi: 10.1007/s11060-012-0930-8
2. Yu S, He L, Zhuang X, Luo B (2001) Pleomorphic xanthoastrocytoma: MR imaging findings in 19 patients. Acta Radiol 52(2):223-228. doi: 10.1258.ar.2010.100221
3. Goncalves VT, Reis F, Queiroz Lde S, Francea M Jr (2013) Pleomorphic xanthoastrocytoma: magnetic resonance imaging findings in a series of cases with histopathological confirmation. Arq Neuropsiquiatr 71(1):35-39
4. Vu TM, Luibinas SV, Gonzales M, Drummond KJ (2012) Malignant potential of pleomorphic xanthoastrocytoma. J Clin Neurosci 19(1):12-20. doi: 10.1016/jocn.2011.07.015
5. Marrucci G, Morandi L (2011) Assessment of MGMT promoter methylation status is pleomorphic xanthoastrocytoma. J Neurooncol 105(2):397-400. doi: 10.1007/s11060-011-0605-6
6. Pignatti F, van den Bent MJ, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084
7. Horbinski C (2013) To BRAF or not BRAF: is that even a question anymore? J Neuropathol Exp Neurol 72(1):207. doi: 10.1097/NEN.0b013e318279fdb
8. Lin A, Rodiguez FJ, Karajannis MA et al (2012) BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 71(1):66-71. doi: 10.1097/NEN.0b013e31823f2cb0
9. Myung JK, Cho H, Park CK, Kim SK, Lee SK, Lee SH, Park SH (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 5(6):430-436
10. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397-405. doi: 10.1007/s00401-0011-0802-6
11. Dias-Santagata D, Lam Q, Vernovsky K, Lennerz JK, Borger DR, Batchelor TT et al (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 6(3):e17948. doi: 10.1371/journal.pone.0017948
12. Marko NF, Weil RJ (2013) The molecular biology of WHO grade II gliomas. Neurosurg Focus 34(2):E1. doi: 10.3171/2012.12.FOCUS12283
13. MacDonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
14. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2506-2507
15. Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600E mutations. N Engl J Med 367:1694-1703
16. Kim KB, Kefford R, Paclick AC et al (2013) Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482-489
17. Trunzer K, Pavlick A, Schuchter L, Gonzalez R, McArthur G et al (2013) Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 31(14):1767-1774